Harrow, Inc. announced the appointment of Amir H. Shojaei, PharmD, PhD, as its new Chief Scientific Officer (CSO). Dr. Shojaei brings 28 years of experience in life sciences, with deep expertise in clinical development, regulatory affairs, and the commercialization of biopharmaceutical products, particularly in ophthalmic indications.
Dr. Shojaei previously served as CSO and Executive Vice President of Clinical Development at AsclepiX Therapeutics and held senior executive roles at Novartis Pharmaceuticals and Shire Pharmaceuticals. Notably, he was instrumental in the clinical development and FDA approval of Xiidra®, a significant dry eye disease treatment, which aligns with Harrow's VEVYE product.
Mark L. Baum, CEO of Harrow, stated that Dr. Shojaei's scientific acumen and proven track record align with Harrow's mission to deliver accessible and affordable eyecare solutions. Dr. Shojaei succeeds Dennis E. Saadeh, PharmD, who is retiring after nearly a decade of service to Harrow.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.